Drug Trial Radar · NCT02458729
The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis
Last checked: Nov 20, 2026Latest source record: Jun 1, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
294
Actual
Start
Aug 2012
Primary completion
Jul 2014
Study completion Jul 2014
Sponsor
- Lead sponsor
- Chang Gung Memorial HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study was to conduct a prospective, randomized, double-blind study and assess the efficacy of and safety for thromboprophylaxis of rivaroxaban in total knee arthroplasty patients when tranexamic acid is used for bleeding prophylaxis.
Conditions
- Osteoarthritis, Knee
Interventions
Tranexamic Acid 5%,5ml/amp (intraoperative)Drug
tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
Tranexamic Acid 5%,5ml/amp (3 hours after operation)Drug
tranexamic acid 1g administered intravenously 3 hours after operation
0.9% Normal Saline (intraoperative)Drug
0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
0.9% Normal Saline (3 hours after operation)Drug
0.9% Normal Saline 20ml administered intravenously 3 hours after operation
rivaroxaban (10mg)Drug
Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of any deep-vein thrombosis, non-fatal pulmonary embolism, or all-cause mortalityTime frame: within 15 days after surgery (2 days after the last dose of rivaroxaban )
- Incidence of major bleeding after the first dose of rivaroxaban and all death related to postoperative bleedingsTime frame: within 15 days after surgery (2 days after the last dose of rivaroxaban )
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kaohsiung Chang Gung Memorial Hospital
Koahsiung, Taiwan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.